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p90RSKCardiac hypertrophy involves the growth of heart muscle cells and is driven by faster protein synthesis which
involves increased ribosome biogenesis. However, the signaling pathways that link hypertrophic stimuli
to faster ribosome production remain to be identiﬁed. Here we have investigated the signaling pathways
which promote ribosomal RNA synthesis in cardiomyocytes in response to hypertrophic stimulation. We
employed a new non-radioactive labeling approach and show that the hypertrophic agent phenylephrine
(PE) stimulates synthesis of 18S rRNA (made by RNA polymerase I) and 5S rRNA (produced by RNA polymer-
ase III) in adult cardiomyocytes. In many settings, rRNA synthesis is driven by rapamycin-sensitive signaling
through mammalian target of rapamycin complex 1 (mTORC1). However, the activation of rRNA synthesis by
PE is not inhibited by rapamycin, indicating that its regulation involves other signaling pathways. PE stimu-
lates MEK/ERK signaling in these cells. Inhibition of this pathway blocks the ability of PE to activate synthesis
of 18S and 5S rRNA. Furthermore, BI-D1870, an inhibitor of the p90RSKs, protein kinases which are activated by
ERK, blocks PE-activated rRNA synthesis, as did a second p90RSK inhibitor, SL0101. BI-D1870 also inhibits the
PE-stimulated association of RNA polymerase I with the rRNA promoter. These ﬁndings show that signaling
via MEK/ERK/p90RSK, not mTORC1, drives rRNA synthesis in adult cardiomyocytes undergoing hypertrophy.
This is important both for our understanding of themechanisms that control ribosome production and, poten-
tially, for the management of cardiac hypertrophy.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
In the adult myocardium, growth is mediated through changes
in the size of the cardiomyocytes. A major driver of cell growth
is the rate of protein synthesis, reﬂecting the fact that the majority
of dry cell mass is protein. Consistent with this, agents that induce
cardiomyocyte growth (hypertrophy) activate protein synthesisventricular cardiomyocytes;
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NC-ND license.(reviewed in [1]). Cardiac hypertrophy (CH) occurs in response,
e.g., to increased load, and is initially adaptive. However, in conditions
of continued stress, CH leads to loss of cardiomyocytes and to tissue
ﬁbrosis, becoming a major risk factor for heart failure. A better under-
standing of the molecular mechanisms that link pro-hypertrophic
stimuli to increased protein synthesis in cardiomyocytes is needed
to develop therapeutic strategies for CH.
Cellular protein synthesis rates are determined both by the overall
levels of ribosomes and translation factors (‘translational capacity’)
and by their intrinsic activities (‘translational efﬁciency’). The hyper-
trophic agonist PE rapidly stimulates protein synthesis in ARVC [2].
This effect is markedly inhibited by rapamycin, indicating that it
is mediated through the mammalian target of rapamycin complex 1,
mTORC1. Activation of mTORC1 by hypertrophic stimuli such as
PE in ARVC is mediated by MEK/ERK signaling [3–6]. Early studies
demonstrated that ribosome content increases in hypertrophying
rat heart and that increased ribosome synthesis is an early event in
hypertrophy [7,8]. However, it is unclear how hypertrophic stimuli
promote ribosome biogenesis in cardiomyocytes.
Production of new ribosomes requires synthesis of four ribosomal
RNAs (rRNAs) and about 80 ribosomal proteins (Rps) [9]. The three
larger rRNAs are made in the nucleolus by RNA polymerase I (Pol I)
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28S rRNAs. The 5S rRNA is made by Pol III. Studies in cell lines have
revealed that mTORC1 can regulate Pol I and Pol III [9–11].
Previous work on ribosome biogenesis in cardiomyocytes used neo-
natal cardiomyocytes (e.g., [12]), which are far easier tomake andwork
with than adult cardiomyocytes. Here, we have studied the regulation
of rRNA synthesis in primary adult rat cardiomyocytes, where PE drives
cell growth [13]. We show that PE stimulates the synthesis of the 18S
and 5S rRNAs, implying that it activates Pol I and Pol III, respectively.
These effects are blocked by inhibition ofMEK, indicating a requirement
for MEK/ERK signaling. However, PE-activated rRNA synthesis is not
blocked by rapamycin indicating that, unusually, mTORC1 does not
mediate the activation of rRNA production in this setting. Instead, the
stimulation of rRNA synthesis by PE requires the activity of p90RSKs, ki-
nases downstream of ERK [14]. Thus, in cardiomyocytes stimulated
with a hypertrophic agonist, MEK/ERK/p90RSK signaling, and not
mTORC1, appears to be the major driver of activated rRNA synthesis.
2. Materials and methods
2.1. Materials
Chemicals for cardiomyocyte isolation were purchased from BDH-
Merck (Poole, UK) or Sigma-Aldrich unless otherwise stated. Bovine
serum albumin (BSA, fraction V) was from Boehringer Mannheim
and Collagenase (type II) fromWorthington Biochemical, New Jersey.
Nylon monoﬁlament ﬁlter cloth was from Cadish Precision Meshes.
Dialysis tubing of size 5 (MW cut-off: 12–14000 Da) was fromMedicell
International. One mL pastettes were from Alpha Laboratories. Vacuum
ﬁlter unit Stericup sterile PES membrane (0.22 μm pore size) was from
Millipore.
All chemicals and biochemicals for RNA isolation, including
4-thiouridine (4SU), and for the chromatin immunoprecipitation assay
were obtained from Sigma-Aldrich unless otherwise stated. Tissue
culture reagentswere provided by Invitrogen. Trizolwas from Invitrogen
and EZ-Link Biotin-HPDPwas from Pierce. Magnetic Porous Glass (MPG)
Streptavidin beads were purchased from PUREBiotech. Actinomycin-D,
PP242 and rapamycin were supplied by Calbiochem, PD184352 from
Toronto Research Chemicals, and AZD6244 from Selleck Chemicals.
BI-D1870 was obtained from the Division of Signal Transduction Ther-
apy, College of Life Sciences, University of Dundee (UK). A769662
and SL0101 were from TOCRIS Bioscience. L-[35S]methionine and [3H]
uridine were from PerkinElmer. Econoﬂuor scintillation liquid was
from Packard Instruments. Real Time-PCR primers and 2× SYBR
Green qPCR mastermix were purchased from PrimerDesign. 3MM ﬁlter
paper was from Whatman International and nitrocellulose transfer
membrane (0.45 μm pore size) from Bio-Rad.
All phosphospeciﬁc antibodies and anti-ribosomal protein S6 were
from Cell Signaling Technology. Anti-α-tubulin and anti-UBF (H-300)
were from Santa Cruz Biotechnology, as were antibodies for IP of Pol I
(sc-46699) and Pol II (sc-47701). Appropriatemarker proteins were in-
cluded on all gels and immunoblots, and were used to ensure that the
antibodies did indeed detect the protein bands of the expected sizes.
2.2. Preparation, maintenance and treatment of ARVC
Adult rat ventricular cardiomyocytes were isolated and maintained
in culture as described [15,16]. Adult male Sprague–Dawley rats
(250–300 g) were from the Biomedical Research Facility, University
of Southampton.
2.3. Assay of uridine uptake into ARVC
Uridine transport wasmonitored in cultured ARVC cells inmedium
either containing or lacking Na+ ions, using a method based on those
used in earlier studies [17–19].2.4. Analysis of RNA dynamics using 4SU labeling
The synthesis and decay of labeled RNA were isolated and mea-
sured as previously described [20,21]. Brieﬂy, 4SU is incorporated
into newly-synthesized RNA; following cell lysis, 4SU tagged RNA is
covalently coupled to biotin, and isolated on streptavidin beads.
After reverse-transcription to cDNA, the quantity of any RNA of inter-
est can be determined by real-time PCR using appropriate primers.
2.5. qChIP analysis
Chromatin immunoprecipitation (ChIP)was performed as described
previously with modiﬁcations [22,23]. Cross-linking was achieved with
1% formaldehyde for 5 min at an ambient temperature and the cells
were sonicated eighteen times for 30 s.
Primers for qPCR analysis of ChIP reactions were β-actin
(Primerdesign, Southampton, UK), ENH (sense: AGGAGGCCGGGCA
AGCA, antisense: CCTCCTTGTTAGAGACCGTCCTTAA), UCE (sense:
AGTTGTTCCTTTGAGGTCCGGT, antisense: AGGAAAGTGACAGGCCAC
AGAG) and CORE (sense: AGTTGTTCCTTTGAGGTCCGGT, antisense:
CAGCCTTAAATCGAAAGGGTCT). The relative level of DNA binding
was analysed using primers speciﬁc for the indicated regions of the
Pol I promoter by qRT-PCR. Average values of precipitated DNA
were normalized to input control.
3. Results and discussion
3.1. PE stimulates the synthesis of new rRNAs in ARVC
We applied a non-radioactive procedure to tag and quantify
newly-made rRNA whereby cells are incubated with 4SU which is in-
corporated into new RNA molecules. Following cell lysis, labeled RNA
molecules are covalently linked to biotin and then isolated. After
reverse transcription (RT), quantitative real-time PCR (RT-qPCR) is
used to measure the levels of any RNA molecule of interest.
To assess whether transferring the cells to medium containing
4SU affected their response to PE, we incubated ARVC for 30 min in
medium containing or lacking 4SU to treatment with PE for times
up to 1 h. As expected from our earlier studies [2], PE rapidly induced
the phosphorylation (activation) of ERK (Fig. 1A). The presence of
4SU did not affect this. To assess activation of mTORC1 signaling, we
looked at the phosphorylation of Rp S6 (Fig. 1A). As reported earlier
[2], PE increased S6 phosphorylation and neither the timing nor the
extent of this response was affected by 4SU (Fig. 1A).
Activation of rRNA transcription has previously been shown to be
slow in neonatal cardiomyocytes [12]. Therefore, to assess whether
PE activates rRNA synthesis, ARVC were treated with PE for 20 h
prior to the addition of 4SU. In some cases, cells were treated with ac-
tinomycin D (2μg/mL), which inhibits transcription by Pol I, Pol II and
Pol III, prior to addition of 4SU. In the absence of actinomycin D, we
observed labeling of transcripts made by each of these polymerases
(18S rRNA, Pol I; actin, Pol II; and 5S rRNA, Pol III; Fig. 1B). Incorporation
of 4SU into each of themwas enhanced by PE, indicating that PE stimu-
lates the transcription of each of these genes, including rRNAs. Impor-
tantly labeling was completely blocked by actinomycin D (Fig. 1B),
conﬁrming that this method only detects newly-synthesized RNAs.
By 12 h of PE treatment, a small increase in the labeling of 18S
rRNA was observed (Fig. 1C), but no signiﬁcant changes in 5S or
actinwere apparent (Fig. 1C). After 24 h treatment,muchmore robust
increases in all three were observed (Fig. 1C); we therefore selected
this as the time-point for further experiments.
Previous work, using neonatal rat cardiomyocytes [12,24], indi-
cated that hypertrophic stimuli increase the cellular levels of up-
stream binding factor (UBF; a component of the Pol I machinery)
and Brf1 (a component of TFIIIB, which is a Pol III-speciﬁc transcrip-
tion factor). UBF levels were also increased in vivo after one week of
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Fig. 1. Phenylephrine enhances synthesis of rRNA in ARVC. (A) ARVC were preincubated in medium containing or lacking 4SU for 30 min and 10 μmol/L PE was then added for the
indicated times (minutes). After lysis, equal amount of lysates (by protein) was analysed by SDS-PAGE and immunoblot using the indicated antibodies. (B,C) ARVC were treated
with 10 μmol/L PE and labeled with 4SU as indicated, actinomycin D being added where shown. Samples were processed for isolation of RNA and quantitation of 4SU-labeled
RNA by qPCR. Data are normalized to total 18S rRNA with levels in untreated cells being set at unity. (C) Data are presented as mean ± SEM (n = 3). (D) ARVC were treated
with PE (10 μM) and/or BI-D1870 (10 μM) for 24 h. Cells were lysed and equal amounts of protein were analysed by SDS-PAGE/immunoblot using the indicated antibodies.
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both 18S rRNA and 5S rRNA by 24 h, there was no detectable change
in levels of UBF or Brf1 (Fig. 1D). Thus, stimulation of rRNA synthesis
by PE in ARVC does not require increased levels of UBF or Brf1, but
likely involves activation of pre-existing components of the Pol I/III
machinery.
Before its incorporation into new RNA molecules, 4SU must enter
the cells. It was therefore important to test whether relevant signaling
inhibitors affected uridine uptake [26,27]. Linear uptake of [3H]uridine
into ARVCwas observed up to 90 s (Fig. 2A); linear rates of net uptake
are not maintained at longer times, because the nucleoside trans-
porters are equilibrative, not concentrative. PE did not affect the rate
of uridine uptake (Fig. 2B). Because a previous report indicated that
very high concentrations of rapamycin (10 μmol/L) inhibited uptake
of [3H]uridine into human K562 cells [26], we ﬁrst assessed what
concentration of rapamycin was required for maximal inhibition
of mTORC1 signaling in ARVC, as judged from the phosphorylation
of S6 at Ser240/244, speciﬁc substrates for the mTORC1-activatedS6 kinases [28]. 100 nmol/L was required to block this completely
(Fig. 2C) and this concentration was used in subsequent experiments.
At this concentration, rapamycin reduced the uptake of [3H]uridine
into ARVC (Fig. 2B).
Importantly for the work described below, neither the MEK in-
hibitor AZD6244 [29] (Fig. 2D) nor the p90RSK inhibitor BI-D1870
[30] (Fig. 2E) signiﬁcantly affected uridine uptake. They can therefore
be used to study the regulation of rRNA synthesiswithout interference
from effects on nucleoside transport.
3.2. Rapamycin does not block PE-stimulated rRNA synthesis
To examine whether activation of rRNA synthesis by PE requires
mTORC1, we studied the effect of rapamycin. Rapamycin decreased
both basal and PE-stimulated synthesis of 18S and 5S rRNA (Fig. 3A,B).
The reduced basal rate of labeling likely reﬂects the partial impairment
of uridine uptake observed in Fig. 2B. Importantly, PE still enhanced
rRNA labeling in the presence of rapamycin, and to at least the same
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Fig. 2. Effects of signaling inhibitors on uptake of [3H]uridine into ARVC. (A) ARVC were incubated in medium to which 1 μCi/nmol [3H]uridine was added at t = 0. Cells were in-
cubated further as indicated before harvesting and processing for measurement of [3H]uridine uptake. (B) [3H]uridine uptake was measured as for Panel A, but cells were treated
with 10 μmol/L PE and/or 100 nmol/L rapamycin for 16 h prior to the uptake assay. (C) ARVC were treated with different concentrations of rapamycin 30 min prior to stimulation
with 10 μmol/L PE for a further 30 min. Samples of lysate were processed by SDS-PAGE/immunoblot using the indicated antibodies. (D,E) As Panel B but using AZD6244 (5 μmol/L,
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completely blocks PE-induced S6 phosphorylation (Fig. 2C), these
ﬁndings demonstrate that the PE-induced activation of rRNA synthesis
is not mediated via rapamycin-sensitive functions of mTORC1 and
thus, in this case, does not involve the S6 kinases which have been
suggested to promote rRNA synthesis (reviewed [31]). Thus, the control
of rRNA synthesis by PE in ARVC differs from other settings, where
mTORC1 signaling does play a major role [9].
Since some mTOR functions are resistant to rapamycin [32–35],
we used PP242 [32] which, unlike rapamycin, directly inhibits mTOR's
kinase activity and blocks all functions of mTOR. As expected, PP242
blocked PE-induced phosphorylation of S6 at Ser235/236 and
Ser240/244 (Suppl. Fig. S1A) without affecting ERK phosphorylation.
PP242 partially inhibited basal rate 18S and 5S rRNA synthesis
(Suppl. Fig. S1B). PP242 also substantially inhibited the PE-activated
synthesis of both 18S rRNA and, to a lesser extent, 5S rRNA synthesis
(Suppl. Fig. S1B). Nonetheless, and especially for 5S rRNA synthesis,
PE was still able to stimulate rRNA transcription even in the presence
of PP242, indicating that events independent of mTOR are involved.
PP242, like rapamycin, inhibited [3H]uridine uptake by 40-50% in
both PE-treated and control conditions (Suppl. Fig. S1C). Hence, its in-
hibitory effect on basal 4SU-labeling of rRNA likely reﬂects impaireduptake of 4SU, while the partial inhibition of the stimulatory effect
of PE may reﬂect a genuine impairment of rRNA transcription or
increased decay of new rRNA given that inhibition of mTOR affects
rRNA processing [17]. Such effects could be mediated via mTORC2
or rapamycin-insensitive functions of mTORC1; the lack of a speciﬁc
mTORC2 inhibitor precludes us from studying this further.
3.3. PE enhances rRNA synthesis via MEK signaling
As shownhere and previously [2–4], PE activatesMEK/ERK signaling
in ARVC and this mediates its short-term (1–3 h) stimulatory effects
on protein synthesis. To test the role of this pathway in rRNA synthesis,
we used the speciﬁc MEK inhibitor, AZD6244 [29], which completely
blocked PE-induced ERK activation (phosphorylation; Fig. 4A). Consis-
tent with earlier data obtained using other MEK inhibitors [2–4],
AZD6244 also largely inhibited activation of mTORC1 signaling as
manifested by decreased phosphorylation of S6(Ser240/244).
AZD6244 did not signiﬁcantly affect basal 18S rRNA transcription
(Fig. 4B) but completely blocked the stimulation by PE, indicating
that PE activates Pol I via MEK/ERK signaling (independently of
mTORC1, which is also activated by MEK/ERK in ARVC). AZD6244
did not elicit activation of AMPK (which can negatively regulate the
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[37,38] (Fig. 4A).
A second MEK inhibitor, PD184352 [39], also completely blocked
PE-induced 5S and 18S rRNA synthesis, without affecting basal syn-
thesis rates, conﬁrming the importance of MEK in this response
(Suppl. Fig. S2). However, because PD184352 is one of the MEK inhib-
itors that can activate AMPK, we did not use this compound further
in this study.
3.4. Enhances rRNA synthesis via p90RSKs
To assess which signaling components mediate activation of Pol I
and Pol III downstream of MEK/ERK, we used BI-D1870, a potent
and selective inhibitor of the four p90RSK isoforms [30]. Earlier data
(discussed in [40]) indicate that p90RSK2/3 are the main isoforms in
ARVC. Our data (Fig. 5A) conﬁrm this and that their levels are not
altered by PE (Fig. 5A). p90RSKs are activated by ERK [14] and we pre-
viously showed that PE rapidly activates p90RSKs in ARVC [4], and that
BI-D1870 blocks signaling through p90RSKs in these cells [41], as it
also does in neonatal cardiomyocytes [42]. BI-D1870 did not impede
activation of ERK by PE (Fig. 5B); rather, it potentiated it, likely
because it blocks an inhibitory feedback loop, as reported earlier
[30,41]. Extended treatment of ARVC with BI-D1870 (for 24 h) caused
a decrease in the levels of p90RSK2, but not p90RSK3 (Fig. 5A). This may
reﬂect a destabilizing effect of BI-D1870 on its target, the p90RSK2 pro-
tein, but could reﬂect an additional effect of this compound. This effect
was not observed in earlier studies where cells were only treated for
shorter periods with this compound (e.g., [30]).
BI-D1870 did not affect basal labeling of 5S or 18S rRNA, but
completely blocked the stimulation by PE (Figs. 5C,D), indicating
that activation of Pol I and Pol III by PE requires an obligatory input
from p90RSKs. One potential caveat is that BI-D1870 can also interfere
with activation of PKB [41,43]; however, PE does not activate PKB in
ARVC( [2] and Figs. 1A,5B).To extend these data, we also used an additional p90RSK inhibitor,
SL0101 [44] although this compound is a much less potent inhibitor
of p90RSKs as judged from in vitro data [45]. We therefore employed
it at a higher concentration than for BI-D1870 (50 μM, the concentra-
tion generally used in other studies). As shown in Figs. 5E,F, SL0101
strongly inhibited the activation of 18S and 5S rRNA synthesis caused
by PE, but without affecting basal synthesis rates. The latter observa-
tion indicates it very unlikely to affect uridine uptake, while the
observed inhibition of the effect of PE supports the conclusion that
p90RSKs play a key role in mediating the activation of rRNA synthesis
in response to PE. The incomplete inhibition likely reﬂects the lower
potency of this inhibitor, and is consistent with the observation
(Suppl. Fig. S3) that, while BI-D1870 strongly inhibits the PE-induced
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a lesser extent. Given we already have to use a relatively high concen-
tration of SL0101, we were reluctant to test it at even higher levels,
where it may well exert off-target effects.
An earlier study suggested that p90RSK may regulate the activity
of Pol I by phosphorylating TIF-1A [46]. While this may explain the
ability of BI-D1870 to inhibit 18S rRNA synthesis, it does not explain
the equally strong inhibition of 5S synthesis (Fig. 5D). Since the
assembly of new ribosomes requires all four rRNAs, three of which
are derived from the same precursor as 18S rRNA, it was possible
that inhibition of the activation of Pol I indirectly affected the stability
of new 5S rRNA, perhaps because it cannot be incorporated into
new ribosomes without the other rRNAs. To test this possibility, we
conﬁgured the 4SU labeling experiment as a pulse-chase protocol
(Fig. 6A). The data clearly show that BI-1870 causes the decay of
new 18S rRNA and 5S rRNA. This effect is similar to the effects of
rapamycin-induced inhibition of rRNA synthesis in HeLa cells, whichalso promotes decay of new rRNA [17] and may explain the observed
inhibition of the accumulation of new 5S rRNA seen here.
It is potentially relevant that p90RSKs are reported to regulate
mTORC1 signaling [47–49]. However, our earlier data revealed that
BI-D1870 does not interfere with activation of mTORC1 by PE in
ARVC [41]. Thus, p90RSKs control PE-stimulated rRNA transcription
in ARVC directly, rather than via mTORC1. Interestingly, PE induces
nuclear translocation of p90RSK in neonatal cardiomyocytes [50].
Earlier work implied that p90RSKs phosphorylate Ser649 in the
C-terminus of TIF-1A [46]; however, there is no consensus phosphor-
ylation site for the N-terminal kinase domain of these enzymes in this
region of TIF-1A, leading those authors to suggest that phosphoryla-
tion was catalysed by the C-terminal kinase domain (which functions
to activate the N-terminal kinase domain, which in turn trans-
phosphorylates other proteins). However, BI-D1870 inhibits the
N-terminal, not the C-terminal, domain of p90RSKs [30], ruling out this
explanation. While human, mouse and rat TIF-1A sequences contain
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145Z. Zhang et al. / Journal of Molecular and Cellular Cardiology 59 (2013) 139–147theproposed ERK site at Ser633 (humannumbering), the local sequence
around the proposed p90RSK-regulated site does not match the consen-
sus for these kinases and differs signiﬁcantly between these species
(see Fig. 4B of [46]). It seems likely that p90RSKs regulate Pol I by
phosphorylating another substrate. Identifying it requires substantial
additional work, which is unfeasible in ARVC. Our observation that
BI-D1870 completely inhibits the PE-activated synthesis of both 18S
and 5S rRNA, while also causing hyperactivation of ERK, shows that
the p90RSKs play a dominant role in controling rRNA synthesis in ARVC.
Since BI-D1870 clearly inhibits the induction of rRNA synthesis
by PE, we asked whether it also interfered with the rapid activation
of protein synthesis by PE. At times up to about 2 h, we have already
shown that this effect is mediated byMEK/ERK signaling [2,5,6]. ARVC
were incubated with or without PE for 24 h; [35S]methionine was
added 30 min after PE (where added). BI-D1870 clearly does not im-
pede PE-stimulated protein synthesis; in fact, if anything, it causes an
increase (Suppl. Fig. 4A), perhaps reﬂecting its ability to enhance ERK
phosphorylation, ﬁrst reported in [30] and observed in Suppl. Figs. 4B
and Fig. 5B. Thus, at relatively short times up to 24 h, the activation
of protein synthesis by PE presumably reﬂects control of the activities
of components of the translational machinery (e.g., the initiation
and elongation factors which are rapidly stimulated by PE [2,5]),
rather than increased ribosome content. Indeed, the present data
show that rRNA synthesis is only activated slowly in ARVC. Ribosome
levels do increase at longer times in hypertrophying neonatal
cardiomyocytes [51,52] or in vivo [7] and this effect is presumably
important for the sustained faster rates of protein synthesis that
lead to cardiac hypertrophy.3.5. BI-D1870 inhibits the PE-induced recruitment of Pol I to the rRNA
promoter
Since BI-D1870 clearly inhibits the PE-induced synthesis of new
18S rRNA, we used ChIP analysis to ask whether PE promoted the
association of Pol I with the rDNA promoter and whether BI-D1870
affected this. We immunoprecipitated Pol I and used three different
sets of primers (Fig. 7A) to study its association with different parts
of the rDNA promoter. PE greatly enhanced the association of Pol I
with the rRNA promoter and this effect was essentially eliminated by
prior treatment of ARVC with BI-D1870 (Fig. 7B). Similar data were
obtained for each pair of pair of primers, conﬁrming that signaling
through p90RSKs is required for PE-induced recruitment of Pol I to the
45S rRNA promoter. Since PE does not increase UBF levels (Fig. 1D),
these data suggest that PE acutely regulates the function of UBF or
other components of the Pol I transcriptional machinery.
4. Concluding remarks
This is the ﬁrst study of the signaling events that control rRNA syn-
thesis in adult cardiomyocytes. It shows that the hypertrophic agonist
PE stimulates the synthesis of rRNA in adult rat cardiomyocytes, con-
sistent with much earlier data showing that hypertrophy is associated
with increased cardiac ribosome content and faster ribosome synthe-
sis [7]. We show that PE stimulates the synthesis of both 5S rRNA,
made by Pol III, and 18S rRNA, made by Pol I. It is important to note
146 Z. Zhang et al. / Journal of Molecular and Cellular Cardiology 59 (2013) 139–147that our data indicate that MEK/ERK/p90RSK signaling, rather than
signaling through mTORC1, drives rRNA synthesis in response to hy-
pertrophic stimulation of ARVC. This ﬁnding both differentiates the
control of rRNA synthesis from other settings where mTORC1 appears
to play amajor role [9] and also raises the possibility that this pathway
may also promote rRNA synthesis in other situations, e.g., cancer cells
where the corresponding pathway is activated due to oncogenic mu-
tations in Ras or Raf.We note that p90RSKs regulate the sodium/proton
exchanger (NHE-1) in cardiomyocytes (reviewed in [53]) and that the
NHE-1 is implicated hypertrophy ([54]). It will be important to inves-
tigate the possible role of NHE-1 in regulating rRNA synthesis, e.g., via
alterations in intracellular pH.
Interestingly, just prior to submission of this article, p90RSK3 was
shown tobe required for cardiac hypertrophy inneonatal cardiomyocytes
and in vivo in response to pressure overload [55], although themolecular
mechanism(s) underlying its contribution to this process was not
determined. Here, we demonstrate that p90RSKs play a key role in the ac-
tivation of rRNA synthesis in response to hypertrophic stimulation. In-
creased ribosome biogenesis is likely to be important for the sustained
increases in protein synthesis that underlie cardiomyocyte growth. Our
data thus appear consistent with the ﬁndings from other groups that
p90RSK inhibitors hypertrophy in block neonatal myocytes [42,50,55]. It
is nowclearly important to establish howp90RSKs activate rRNA synthesis
in ARVC; insights into this may provide opportunities for intervention
to prevent or reverse cardiac hypertrophy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.yjmcc.2013.03.006.
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